Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.

Wolf S, Johnson S, Perwitasari O, Mahalingam S, Tripp RA.

Clin Transl Immunology. 2017 Mar 31;6(3):e135. doi: 10.1038/cti.2017.8. eCollection 2017 Mar.

2.

Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection.

Perwitasari O, Johnson S, Yan X, Register E, Crabtree J, Gabbard J, Howerth E, Shacham S, Carlson R, Tamir S, Tripp RA.

PLoS One. 2016 Nov 28;11(11):e0167221. doi: 10.1371/journal.pone.0167221. eCollection 2016.

3.

MicroRNA Regulation of Human Genes Essential for Influenza A (H7N9) Replication.

Wolf S, Wu W, Jones C, Perwitasari O, Mahalingam S, Tripp RA.

PLoS One. 2016 May 11;11(5):e0155104. doi: 10.1371/journal.pone.0155104. eCollection 2016.

4.

MicroRNA-555 has potent antiviral properties against poliovirus.

Shim BS, Wu W, Kyriakis CS, Bakre A, Jorquera PA, Perwitasari O, Tripp RA.

J Gen Virol. 2016 Mar;97(3):659-68. doi: 10.1099/jgv.0.000372. Epub 2015 Dec 18.

PMID:
26683768
5.

Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.

Perwitasari O, Yan X, O'Donnell J, Johnson S, Tripp RA.

Assay Drug Dev Technol. 2015 Dec;13(10):638-49. doi: 10.1089/adt.2015.0003.drrr. Epub 2015 Jul 20.

6.

A pioneering countermeasure against measles virus.

Perwitasari O, Tripp RA.

Ann Transl Med. 2015 May;3(Suppl 1):S15. doi: 10.3978/j.issn.2305-5839.2015.02.29. No abstract available.

7.

Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Perwitasari O, Johnson S, Yan X, Howerth E, Shacham S, Landesman Y, Baloglu E, McCauley D, Tamir S, Tompkins SM, Tripp RA.

J Virol. 2014 Sep 1;88(17):10228-43. doi: 10.1128/JVI.01774-14. Epub 2014 Jun 25.

8.

siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.

Perwitasari O, Bakre A, Tompkins SM, Tripp RA.

Pharmaceuticals (Basel). 2013 Jan 28;6(2):124-60. doi: 10.3390/ph6020124.

9.

Targeting cell division cycle 25 homolog B to regulate influenza virus replication.

Perwitasari O, Torrecilhas AC, Yan X, Johnson S, White C, Tompkins SM, Tripp RA.

J Virol. 2013 Dec;87(24):13775-84. doi: 10.1128/JVI.01509-13. Epub 2013 Oct 9.

10.

Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA.

Antimicrob Agents Chemother. 2013 Jan;57(1):475-83. doi: 10.1128/AAC.01532-12. Epub 2012 Nov 5.

11.

Inhibitor of κB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection.

Perwitasari O, Cho H, Diamond MS, Gale M Jr.

J Biol Chem. 2011 Dec 30;286(52):44412-23. doi: 10.1074/jbc.M111.285205. Epub 2011 Nov 7.

12.

Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity.

Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, Akira S, Gill MA, García-Sastre A, Katze MG, Gale M Jr.

J Virol. 2008 Jan;82(1):335-45. Epub 2007 Oct 17.

13.

The cellular protein P58IPK regulates influenza virus mRNA translation and replication through a PKR-mediated mechanism.

Goodman AG, Smith JA, Balachandran S, Perwitasari O, Proll SC, Thomas MJ, Korth MJ, Barber GN, Schiff LA, Katze MG.

J Virol. 2007 Mar;81(5):2221-30. Epub 2006 Dec 13.

14.

Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus.

Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, García-Sastre A, Swayne DE, Katze MG.

Nature. 2006 Oct 5;443(7111):578-81. Epub 2006 Sep 27.

15.

Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.

Kash JC, Mühlberger E, Carter V, Grosch M, Perwitasari O, Proll SC, Thomas MJ, Weber F, Klenk HD, Katze MG.

J Virol. 2006 Mar;80(6):3009-20.

Supplemental Content

Loading ...
Support Center